LCM
PRQR icon

Lynx1 Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Lynx1 Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$970K Buy
521,413
+452,927
+661% +$746K 0.11% 15
2026
Q1 		$111K Hold
68,486
– – 0.02% 21
2025
Q4 		$138K Buy
+68,486
New +$160K 0.03% 21

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Lynx1 Capital Management's PRQR Position: Q2 2026 in Review

Lynx1 Capital Management increased its ProQR Therapeutics (PRQR) stake by 661% in Q2 2026, buying an estimated $746K and bringing the position to 521,413 shares worth $970K. The position accounts for 0.11% of the portfolio, ranked #15.

Lynx1 Capital Management first reported a position in PRQR in Q4 2025 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Lynx1 Capital Management held 521,413 shares of ProQR Therapeutics worth $970K as of Q2 2026.
  • Lynx1 Capital Management bought 452,927 ProQR Therapeutics shares in Q2 2026, an estimated $746K.
  • ProQR Therapeutics made up 0.11% of Lynx1 Capital Management's portfolio in Q2 2026, its #15 holding.
  • Lynx1 Capital Management first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.